JP2005528406A5 - - Google Patents

Download PDF

Info

Publication number
JP2005528406A5
JP2005528406A5 JP2003586149A JP2003586149A JP2005528406A5 JP 2005528406 A5 JP2005528406 A5 JP 2005528406A5 JP 2003586149 A JP2003586149 A JP 2003586149A JP 2003586149 A JP2003586149 A JP 2003586149A JP 2005528406 A5 JP2005528406 A5 JP 2005528406A5
Authority
JP
Japan
Prior art keywords
alkyl
group
compound
nhc
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003586149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528406A (ja
JP4558331B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/011510 external-priority patent/WO2003089428A1/en
Publication of JP2005528406A publication Critical patent/JP2005528406A/ja
Publication of JP2005528406A5 publication Critical patent/JP2005528406A5/ja
Application granted granted Critical
Publication of JP4558331B2 publication Critical patent/JP4558331B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003586149A 2002-04-16 2003-04-14 三環式トロンビンレセプターアンタゴニスト Expired - Fee Related JP4558331B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16
PCT/US2003/011510 WO2003089428A1 (en) 2002-04-16 2003-04-14 Tricyclic thrombin receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010049903A Division JP2010132710A (ja) 2002-04-16 2010-03-05 三環式トロンビンレセプターアンタゴニスト

Publications (3)

Publication Number Publication Date
JP2005528406A JP2005528406A (ja) 2005-09-22
JP2005528406A5 true JP2005528406A5 (enExample) 2009-08-13
JP4558331B2 JP4558331B2 (ja) 2010-10-06

Family

ID=29250954

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003586149A Expired - Fee Related JP4558331B2 (ja) 2002-04-16 2003-04-14 三環式トロンビンレセプターアンタゴニスト
JP2010049903A Withdrawn JP2010132710A (ja) 2002-04-16 2010-03-05 三環式トロンビンレセプターアンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010049903A Withdrawn JP2010132710A (ja) 2002-04-16 2010-03-05 三環式トロンビンレセプターアンタゴニスト

Country Status (33)

Country Link
US (3) US7304078B2 (enExample)
EP (5) EP1860106B1 (enExample)
JP (2) JP4558331B2 (enExample)
KR (1) KR101026929B1 (enExample)
CN (1) CN1659162B (enExample)
AR (1) AR039570A1 (enExample)
AT (3) ATE378330T1 (enExample)
AU (1) AU2003221932B2 (enExample)
BR (1) BRPI0309309B8 (enExample)
CA (1) CA2482858C (enExample)
CY (3) CY1107184T1 (enExample)
DE (3) DE60317493T3 (enExample)
DK (2) DK1495018T3 (enExample)
EC (1) ECSP045368A (enExample)
ES (3) ES2338171T3 (enExample)
FR (1) FR15C0047I2 (enExample)
IL (1) IL164585A (enExample)
LT (1) LTC1495018I2 (enExample)
LU (1) LU92759I2 (enExample)
MX (1) MXPA04010308A (enExample)
MY (1) MY144040A (enExample)
NL (1) NL300746I1 (enExample)
NO (2) NO330500B1 (enExample)
NZ (2) NZ575139A (enExample)
PE (1) PE20040412A1 (enExample)
PL (1) PL214718B1 (enExample)
PT (2) PT2065384E (enExample)
RU (2) RU2329264C9 (enExample)
SG (1) SG164279A1 (enExample)
SI (2) SI2065384T1 (enExample)
TW (1) TWI343919B (enExample)
WO (1) WO2003089428A1 (enExample)
ZA (1) ZA200408342B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
DE602005009355D1 (de) * 2004-05-28 2008-10-09 Schering Corp Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
CA2582353A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
EP1848705B1 (en) 2005-01-14 2010-02-24 Schering Corporation Exo- and diastereo- selective syntheses of himbacine analogs
CN101137614A (zh) * 2005-01-14 2008-03-05 先灵公司 喜巴辛类似物的手性炔丙醇和酯中间体的制备
US7772276B2 (en) * 2005-01-14 2010-08-10 Schering Corporation Exo-selective synthesis of himbacine analogs
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
PT1853592E (pt) * 2005-01-14 2011-05-10 Schering Corp S?ntese de an?logos da himbacina
AU2006230292A1 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
US20070219154A1 (en) * 2005-12-20 2007-09-20 Suxing Liu Methods for preventing and/or treating a cell proliferative disorder
AU2006331583A1 (en) * 2005-12-22 2007-07-05 Schering Corporation Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
AR060354A1 (es) * 2006-04-06 2008-06-11 Schering Corp Terapias de combinacion antagonistas receptor trombina (tra)
CA2650404A1 (en) * 2006-04-13 2007-10-25 Schering Corporation Fused ring thrombin receptor antagonists
EP2032560B1 (en) * 2006-06-29 2013-05-01 Merck Sharp & Dohme Corp. Substituted bicyclic and tricyclic thrombin receptor antagonists
TWI367112B (en) 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
WO2008042422A2 (en) 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
AU2007320029A1 (en) * 2006-10-04 2008-05-22 Schering Corporation Thrombin receptor antagonists based on the modified tricyclic unit of himbacine
MX2009006873A (es) * 2006-12-22 2009-07-03 Schering Corp Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
BRPI0809095A2 (pt) * 2007-03-23 2014-09-09 Schering Corp Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina
WO2009097970A1 (de) 2008-02-05 2009-08-13 Sanofi-Aventis Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
AU2009211888B2 (en) 2008-02-05 2013-06-20 Sanofi Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
WO2009143039A2 (en) 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
MX2011012861A (es) 2009-06-04 2012-01-25 Schering Corp Metabolito activo de un antagonista de receptor de trombina.
WO2010144339A2 (en) 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
WO2011128421A1 (de) 2010-04-16 2011-10-20 Sanofi Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
ES2527535T3 (es) 2010-04-16 2015-01-26 Sanofi Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 [6+5]접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
EP2822557B1 (en) 2012-03-06 2017-08-23 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
US9604971B2 (en) 2013-07-22 2017-03-28 Aralez Pharmaceuticals Trading Dac Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
WO2015026693A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
EP3035930A4 (en) * 2013-08-22 2017-03-08 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药(苏州)股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药(苏州)股份有限公司 一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
TW201738221A (zh) * 2016-04-22 2017-11-01 Jiangsu Tasly Diyi Pharmaceutical Co Ltd 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
CN116133660B (zh) 2020-07-22 2025-05-02 詹森药业有限公司 可用作因子XIa抑制剂的化合物
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
TW197435B (enExample) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
GB9102862D0 (en) * 1991-02-11 1991-03-27 Erba Carlo Spa N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
TR200001480T2 (tr) * 1997-11-25 2000-09-21 Schering Corporation Trombin reseptör antagonistleri
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
MY130642A (en) 2000-06-15 2007-07-31 Schering Corp Nor-seco himbacine derivatives useful as thrombin receptor antagonists
MXPA04003610A (es) 2001-10-18 2004-07-27 Schering Corp Analogos de himbacina como antagonistas del receptor de trombina.

Similar Documents

Publication Publication Date Title
JP2005528406A5 (enExample)
CA2482858A1 (en) Tricyclic thrombin receptor antagonists
RU2006113638A (ru) Антагонисты рецептора тромбина
AR074165A1 (es) Antagonistas de heteroalquilo de receptores de prostaglandina d2 y composiciones farmaceuticas
JP2020500207A5 (enExample)
RU2004115114A (ru) Аналоги гимбацина как антагонисты рецептора тромбина
CA2410177A1 (en) Thrombin receptor antagonists
JP2015522650A5 (enExample)
JP2010539110A5 (enExample)
JP2014532070A5 (enExample)
CY1112024T1 (el) Αναστολεις υποδοχεων adp αιμοπεταλιων
JP2008510828A5 (enExample)
JP2011520967A5 (enExample)
JP2017530959A5 (enExample)
JP2008510691A5 (enExample)
RU2011123672A (ru) Гетероароматические соединения для применения в качестве hif ингибиторов
MA29119B1 (fr) Derives de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
CA2487365A1 (en) Piperidine derivatives as potassium channel blockers
JP2007533741A5 (ja) Bace阻害剤として有用なピロリジン誘導体
JP2007507519A5 (enExample)
DK1507775T3 (da) Heterocykliske forbindelser som hæmmer leukocyt-adhæsion medieret af alfa-4-integriner
JP2018529780A5 (enExample)
JP2017526614A5 (enExample)
MX2007005155A (es) Nuevos derivados de aminopiridina que tienen accion inhibidora selectiva de la aurora a.
JP2019522628A5 (enExample)